Beta-blocker therapy stands as a cornerstone in the realm of cardiovascular medicine, offering a multifaceted approach to address various conditions. These pharmacological agents, commonly known as beta-blockers, exert their therapeutic effects by antagonizing the impact of adrenaline, resulting in a reduction of heart rate and blood pressure. Widely prescribed to manage hypertension, angina, and specific cardiac arrhythmias, beta-blockers showcase their effectiveness in diverse cardiovascular scenarios. Notably, their role extends to the management of heart failure, where they contribute to enhancing cardiac function and alleviating symptoms. Post-myocardial infarction care also heavily relies on beta-blocker therapy to prevent subsequent cardiovascular events. Beyond cardiovascular applications, these agents demonstrate versatility, occasionally finding use in mitigating symptoms associated with anxiety and migraine headaches. While generally well-tolerated, the individualized consideration of medical histories and potential contraindications is imperative in the prescription of beta-blocker therapy. A collaborative approach between healthcare providers and patients remains paramount to ensuring optimal cardiovascular health management.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States